Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
This phase II trial investigates how well duloxetine and neurofeedback training work in
treating patients with chemotherapy induced peripheral neuropathy. Duloxetine is a type of
serotonin and norepinephrine reuptake inhibitor that increases the amount of certain
chemicals in the brain that help relieve depression and peripheral neuropathy. Neurofeedback
training is a type of therapy that uses an electroencephalograph (EEG) and a computer
software program to measure brain wave activity and may help teach patients with peripheral
neuropathy (nerve damage) how to change their own brain waves to lower their feelings of
neuropathy and help improve their overall quality of life. Giving duloxetine and
neurofeedback training may work better in treating peripheral neuropathy caused by
chemotherapy compared to duloxetine or neurofeedback training alone.